CKD-333 Tab.

DRUG2 trials

Sponsors

Chong Kun Dang Pharmaceutical

Conditions

Cardiovascular Disease

Phase 1

Clinical Trial to Evaluate the Safety and Pharmacokinetic Characteristics in Healthy Volunteers

Chong Kun Dang PharmaceuticalCardiovascular Disease

Start: 2020-07-14End: 2021-01-01Target: 51Updated: 2020-07-22

Clinical Study to Evaluate the Pharmacokinetic Profiles and Safety of CKD-333 Low Dose in Healthy Volunteers

Chong Kun Dang PharmaceuticalCardiovascular Disease

Start: 2020-11-11End: 2021-04-27Target: 51Updated: 2020-11-02

Related Papers

Pharmacokinetic Comparison of a Fixed-Dose Combination of Candesartan Cilexetil/Amlodipine/Atorvastatin Versus Co-administration of Individual Formulations in Healthy Participants

Advances in Therapy2024-05-211 citations